PhaseRx (PZRX) IPO Opens Up 10%

Today's IPO for PhaseRx, Inc. (NASDAQ: PZRX) opened for trading at $5.50 after pricing 3,700,000 shares of common stock at an initial public offering price of $5.00.

Laidlaw & Company (UK) Ltd. and Roth Capital Partners are acting as joint book-running managers for the offering.

PhaseRx is a preclinical biopharmaceutical company dedicated to developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). The Company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle, Wash.

You May Also Be Interested In

• Some investors push Anthropic to cut IPO valuation to $1.5 trillion - report
• Strive prices upsized IPO of preferred stock at $90 per share
• Vogenx starts Phase 2b trial for post-bariatric hypoglycemia drug